Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

MYSTERIOUS: Earnings preview what to expect from abbvie s report - You Need To See This

With a market cap of $309.7 billion, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company, engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. Based in North Chicago, Illinois, the company’s offerings include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta/Venclyxto, and others.

The company is expected to report its Q1 earnings on Friday, Apr. 25, before the market opens. Ahead of the event, analysts expect ABBV to report an EPS of $2.38 per share, up 3% from $2.31 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in all of the past four quarters. Its adjusted EPS of $2.16 in the recent quarter surpassed analysts’ expectations by 1.4%, driven by a solid performance in its Immunology, Oncology, Neuroscience, and Aesthetics portfolio.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.